Mavodelpar
Modify Date: 2024-04-03 20:59:05
Mavodelpar structure
|
Common Name | Mavodelpar | ||
|---|---|---|---|---|
| CAS Number | 1604815-32-8 | Molecular Weight | 537.55 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C31H29FNNaO5 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of MavodelparMavodelpar (REN001) is a selective PPARδ agonist. Mavodelpar suppresses glomerular injury and renal fibrosis. Mavodelpar can be used for the research of primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD)[1]. |
| Name | Mavodelpar |
|---|
| Description | Mavodelpar (REN001) is a selective PPARδ agonist. Mavodelpar suppresses glomerular injury and renal fibrosis. Mavodelpar can be used for the research of primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD)[1]. |
|---|---|
| Related Catalog | |
| In Vivo | Mavodelpar (10 mg/kg；腹腔注射，10 mg/kg，每日 1 次，6-17 周龄) 可有效抑制肾小球损伤和肾纤维化，并降低纤维化相关蛋白的水平[1]。 Animal Model: Male and female B6129SF1-Col4a3-/- mice[1] Dosage: 10 mg/kg Administration: Intraperitoneal injection; 10 mg/kg, once daily, from 6 to 17 weeks of age Result: Suppressed proteinuria and blood urea nitrogen (BUN) levels. Reduced glomerular injury, renal fibrosis, phosho-Stat3 and connective tissue growth factor (CTGF) levels. Decreased the expression level of the activated fibroblast marker alpha-SMA and Collagen I and IV. |
| References |
| Molecular Formula | C31H29FNNaO5 |
|---|---|
| Molecular Weight | 537.55 |